Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

NCT02911142 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

17

Enrollment

NIH

Sponsor class

Conditions

Primary Effusion Lymphoma
B-Cell Neoplasm

Interventions

DRUG: Lenalidomide
DRUG: Rituximab
DRUG: Prednisone
DRUG: Etoposide
DRUG: Doxorubicin
DRUG: Vincristine
DRUG: Cyclophosphamide
DIAGNOSTIC_TEST: CT of neck, chest, abdomen and pelvis
DIAGNOSTIC_TEST: 18FDG-PET scan
DIAGNOSTIC_TEST: MRI Brain
PROCEDURE: Bone marrow biopsy
DIAGNOSTIC_TEST: EKG
DIAGNOSTIC_TEST: Echocardiogram
DIAGNOSTIC_TEST: Ultrasound
DIAGNOSTIC_TEST: Bronchoscopy
DIAGNOSTIC_TEST: Endoscopy
DIAGNOSTIC_TEST: CXR: PA/lat/decub

Sponsor

National Cancer Institute (NCI)